Rhein Biotech GmbH [Dynavax Europe]

Rhein Biotech GmbH [Dynavax Europe], a subsidiary of Dynavax Technologies Corporation headquartered in Düsseldorf, Germany, develops, manufactures, licenses-out and markets biopharmaceutical products and technologies. Rhein Biotech GmbH [Dynavax Europe] was acquired by Dynavax Technologies in April 2006. For further information please visit the website of Dynavax Technologies.

 

Dynavax Technologies Corporation 

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR-9 agonist-based products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control inflammation. Dynavax's pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine in Phase 3; and a therapy for non-Hodgkins lymphoma in Phase 2. Its preclinical asthma and COPD programs are partnered with AstraZeneca. Funding for the company's other preclinical programs in hepatitis B, hepatitis C, cancer and for an influenza vaccine have been provided by NIH and Symphony Dynamo, but represent future partnering opportunities. For further information please visit the website of Dynavax Technologies.

Rhein Biotech GmbH
Dynavax Europe
Eichsfelder Strasse 11
D-40595 Düsseldorf

Phone: +49 (0)211 7 58 45 0
Fax: +49 (0)211 7 58 45 130
E-Mail: info(at)rheinbiotech.de